Insider filing · LLY
Daniel Skovronsky
EVP, CSO & Pres. LRL & LLY Imm
profile →
Eli Lilly and Company
LLY · Healthcare · 118 filings in 24 months
ticker →
Daniel Skovronsky sold $4.3M of Eli Lilly and (LLY)
Executed Feb 10 2025, disclosed Feb 12 2025, 2 days later.
Value, as filed
$4.3M
5,000 sh across 3 lots
Executed
Feb 10 2025
the trade date, as filed
Disclosed
Feb 12 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
DSDaniel Skovronsky (EVP, CSO & Pres. LRL & LLY Imm) filed 2 Form 4 reports in the past 24 months (1 purchase, 1 sale), most often in Eli Lilly and Company (LLY). Across 1 priced purchase filing, the average 21-session return was +18.3% from execution and +18.3% from disclosure (delay-adjusted; derived). The largest single filing was $4.3M of LLY (5,000 sh across 3 lots, as filed), executed Feb 10 2025.
The name
LLYHealthcare · Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Jap…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Daniel Skovronsky in LLY
LLYPURCHASE
Eli Lilly and Company
$634K1,000 sh × $634.40
Exec Aug 12 2025
Filed Aug 12 2025 · 4:20 PM ET